The success of both monoclonal antibodies prepared the ground for immunotherapy in MM treatment and led to recent approval of the antibody-drug conjugate (ADC) belantamab mafodotin and the chimeric antigen receptor (CAR) T cell product idecabtagene vicleucel, both directed against the B cell maturation antigen (BCMA/CD269), which is exclusively expressed on healthy and malignant plasma cells (4, 5). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.